Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.69 |
| ▸ | CASP1 | P29466 | 1/20 | 0.64 |
| ▸ | CASP4 | P49662 | 1/20 | 0.64 |
| ▸ | CASP5 | P51878 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447356 | 1.00 | SIGMAR1 (0.77) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| Hydrochloric Acid SCHEMBL16825187 | 0.98 | SIGMAR1 (0.74) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL3162705 | 0.98 | SIGMAR1 (0.79) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL30774908 | 0.95 | SIGMAR1 (0.79) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL19206069 | 0.92 | SIGMAR1 (0.70) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL28186295 | 0.91 | SIGMAR1 (0.90) | SIGMAR1ALDH1A1KDM4ECASP1CASP4 | |
| SCHEMBL20804357 | 0.91 | SIGMAR1 (0.90) | SIGMAR1ALDH1A1KDM4ECASP1CASP4 | |
| Benzylamine SCHEMBL28105111 | 0.91 | SIGMAR1 (0.74) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL24495483 | 0.89 | DRD4 (0.68) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL19206085 | 0.88 | SIGMAR1 (0.64) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0117345-B1 | AMINOPYRIMIDINONES AS HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-02-28 | — | — | EP | claimed |
| EP-0117345-A2 | Aminopyrimidinones as histamine H2-antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-09-05 | — | — | EP | claimed |
| WO-2022109209-A1 | SMALL MOLECULE COMPOUNDS AND COMPOSITIONS | TELO THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-107567445-A | It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor | 坎塞拉有限公司 | 2018-01-09 | — | — | CN | disclosed |
| EP-3083584-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-10-26 | — | — | EP | disclosed |
| CN-105859654-A | Method for synthesizing Roxatidine intermediate 3-(1-piperidinyl methyl) phenol | 安徽禾益化学股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| WO-2015090232-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-25 | — | — | WO | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | PROXIMAGEN LTD. (GB) | 2013-12-05 | — | — | US | disclosed |
| EP-2668157-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | Proximagen Limited (GB) | 2013-12-04 | — | — | EP | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-4540699-A | N-Substituted pyridinones having histamine H2 -antagonist activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-09-10 | — | — | US | disclosed |
| EP-0132914-A2 | Imidazolinone derivatives as histamine H2-antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-02-13 | — | — | EP | disclosed |
| WO-1984004304-A1 | AMINOIMIDAZOLONE DERIVATIVES AS HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1984-11-08 | — | — | WO | disclosed |
| EP-0117345-A2 | Aminopyrimidinones as histamine H2-antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-09-05 | — | — | EP | disclosed |
| US-4220357-A | PRESSURE SENSITIVE OR HEAT SENSITIVE SYSTEMS | STERLING DRUG INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4209618-A | COLOR PRECURSORS IN PRESSURE-SENSITIVE DUPLICATING SYSTEMS AND HEAT-SENSITIVE MARKING SYSTEMS | STERLING DRUG INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4096176-A | Benzoylbenzoic acids | STERLING DRUG INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-4094877-A | SUBSTITUTED 3,3-DIPHENYLPHTHALIDES AS COLOR PRECURSORS | STERLING DRUG INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-4032527-A | COLOR PRECURSORS | STERLING DRUG INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | F2RL1, F2R, F2RL3 | SIGMAR1 675/4885ALDH1A1 4306/4885KDM4E 4322/4885 |
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | SIGMAR1 1170/4885ALDH1A1 3113/4885KDM4E 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.